Literature DB >> 27832534

Cell-Penetrating Peptide-Mediated Delivery of Cas9 Protein and Guide RNA for Genome Editing.

Bharathi Suresh1,2, Suresh Ramakrishna3,4, Hyongbum Kim5,6,7.   

Abstract

The clustered, regularly interspaced, short palindromic repeat (CRISPR)-associated (Cas) system represents an efficient tool for genome editing. It consists of two components: the Cas9 protein and a guide RNA. To date, delivery of these two components has been achieved using either plasmid or viral vectors or direct delivery of protein and RNA. Plasmid- and virus-free direct delivery of Cas9 protein and guide RNA has several advantages over the conventional plasmid-mediated approach. Direct delivery results in shorter exposure time at the cellular level, which in turn leads to lower toxicity and fewer off-target mutations with reduced host immune responses, whereas plasmid- or viral vector-mediated delivery can result in uncontrolled integration of the vector sequence into the host genome and unwanted immune responses. Cell-penetrating peptide (CPP), a peptide that has an intrinsic ability to translocate across cell membranes, has been adopted as a means of achieving efficient Cas9 protein and guide RNA delivery. We developed a method for treating human cell lines with CPP-conjugated recombinant Cas9 protein and CPP-complexed guide RNAs that leads to endogenous gene disruption. Here we describe a protocol for preparing an efficient CPP-conjugated recombinant Cas9 protein and CPP-complexed guide RNAs, as well as treatment methods to achieve safe genome editing in human cell lines.

Entities:  

Keywords:  Cas9 conjugation; Cas9 protein purification; Dialysis; In vitro sgRNA synthesis; Protein delivery; T7E1 assay

Mesh:

Substances:

Year:  2017        PMID: 27832534     DOI: 10.1007/978-1-4939-6518-2_7

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  21 in total

Review 1.  Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications.

Authors:  Chang Liu; Li Zhang; Hao Liu; Kun Cheng
Journal:  J Control Release       Date:  2017-09-11       Impact factor: 9.776

Review 2.  Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects.

Authors:  Hongyi Li; Yang Yang; Weiqi Hong; Mengyuan Huang; Min Wu; Xia Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-01-03

Review 3.  CRISPR-Cas9-Based Technology and Its Relevance to Gene Editing in Parkinson's Disease.

Authors:  Mujeeb Ur Rahman; Muhammad Bilal; Junaid Ali Shah; Ajeet Kaushik; Pierre-Louis Teissedre; Małgorzata Kujawska
Journal:  Pharmaceutics       Date:  2022-06-13       Impact factor: 6.525

Review 4.  Genetic and Covalent Protein Modification Strategies to Facilitate Intracellular Delivery.

Authors:  Justin M Horn; Allie C Obermeyer
Journal:  Biomacromolecules       Date:  2021-12-02       Impact factor: 6.978

Review 5.  CRISPR-Cas9: A Preclinical and Clinical Perspective for the Treatment of Human Diseases.

Authors:  Garima Sharma; Ashish Ranjan Sharma; Manojit Bhattacharya; Sang-Soo Lee; Chiranjib Chakraborty
Journal:  Mol Ther       Date:  2020-09-20       Impact factor: 11.454

Review 6.  New approaches to moderate CRISPR-Cas9 activity: Addressing issues of cellular uptake and endosomal escape.

Authors:  Maja van Hees; Sofie Slott; Anders Højgaard Hansen; Heon Seok Kim; Hanlee P Ji; Kira Astakhova
Journal:  Mol Ther       Date:  2021-06-04       Impact factor: 11.454

Review 7.  Cell-penetrating peptides and their utility in genome function modifications (Review).

Authors:  Maciej Gagat; Wioletta Zielińska; Alina Grzanka
Journal:  Int J Mol Med       Date:  2017-10-04       Impact factor: 4.101

8.  Membrane permeabilizing amphiphilic peptide delivers recombinant transcription factor and CRISPR-Cas9/Cpf1 ribonucleoproteins in hard-to-modify cells.

Authors:  Thomas Del'Guidice; Jean-Pascal Lepetit-Stoffaes; Louis-Jean Bordeleau; Joannie Roberge; Vanessa Théberge; Coraline Lauvaux; Xavier Barbeau; Jessica Trottier; Vibhuti Dave; Denis-Claude Roy; Bruno Gaillet; Alain Garnier; David Guay
Journal:  PLoS One       Date:  2018-04-04       Impact factor: 3.240

9.  CRISPR/Cas9 mediated high efficiency knockout of the eye color gene Vermillion in Helicoverpa zea (Boddie).

Authors:  Omaththage P Perera; Nathan S Little; Calvin A Pierce
Journal:  PLoS One       Date:  2018-05-17       Impact factor: 3.240

10.  Non-viral delivery of CRISPR/Cas9 complex using CRISPR-GPS nanocomplexes.

Authors:  Piyush K Jain; Justin H Lo; Santosh Rananaware; Marco Downing; Apekshya Panda; Michelle Tai; Srivatsan Raghavan; Heather E Fleming; Sangeeta N Bhatia
Journal:  Nanoscale       Date:  2019-10-31       Impact factor: 7.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.